Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications

  title={Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications},
  author={Shinichi Kondo and Kunimoto Hotta},
  journal={Journal of Infection and Chemotherapy},
  • S. Kondo, K. Hotta
  • Published 1999
  • Chemistry, Biology
  • Journal of Infection and Chemotherapy
Abstract The critical resistance mechanisms of aminoglycoside antibiotics in bacteria of clinical importance are the enzymatic N-acetylation, O-phosphorylation, and O-nucleotidylation that generally result in the inactivation of aminoglycosides. To overcome such resistance mechanisms, dibekacin (3′,4′-dideoxykanamycin B) was developed as the first rationally designed semisynthetic aminoglycoside, based on the enzymatic 3′-O-phosphorylation of kanamycin. Subsequently, amikacin, netilmicin, and… 

Amikacin: Uses, Resistance, and Prospects for Inhibition

Small molecules as well as complexes ionophore-Zn+2 or Cu+2 were found to inhibit the acetylation reaction and induced phenotypic conversion to susceptibility in bacteria harboring the aac(6′)-Ib gene.

Structural Basis of APH(3′)-IIIa-Mediated Resistance to N1-Substituted Aminoglycoside Antibiotics

The structure shows that butirosin A binds to the enzyme in a manner analogous to other 4,5-disubstituted aminoglycosides, and the flexible antibiotic-binding loop is key to the accommodation of structurally diverse substrates.

Biosynthesis of (2R)-4-amino-2-hydroxybutyric acid, unique and biologically significant substituent in butirosins.

It is anticipated that AHBA is derived from rather simple amino acid and that the hydroxy group at C-2 may be introduced at a later stage of biosynthesis, which may turn out to be beneficial in the future to develop diversities of this class of antibiotics.

Novel Aminoglycoside 2″-Phosphotransferase Identified in a Gram-Negative Pathogen

Steady-state kinetic studies demonstrated that GTP, and not ATP, is the preferred cosubstrate for APH(2″)-If, which confers resistance to the 4,6-disubstituted aminoglycosides kanamycin, tobramycin, dibekacin, gentamicin, and sisomicin.

Conformations of antibiotics in active sites of aminoglycoside-detoxifying enzymes

The extensive use of antibiotics, such as aminoglycosides, over many years, has put tremendous pressure on bacteria, which has responded by conformations of Antibiotics in Active Sites of Aminoglycoside-Detoxifying Enzymes.

Isolation and Thermodynamic Characterization of Aminoglycoside Nucleotidyltransferase (2″)-Ia

The refolded enzyme is monomeric in solution and has similar kinetic properties and substrate selectivity to the enzyme isolated in soluble form and has been determined to be direct dilution of solubilized inclusion bodies into 0.1 M Tris-HCl pH 8.5.

Plasticity of Aminoglycoside Binding to Antibiotic Kinase APH(2″)-Ia

It is found that APH(2″)-Ia maintains a preferred mode of binding aminoglycosides by using the conserved neamine rings when possible, with flexibility that allows it to accommodate additional rings, which explains the low rates of noncanonical phosphorylation activities seen in enzyme assays.

Structural Analysis of the Tobramycin and Gentamicin Clinical Resistome Reveals Limitations for Next-generation Aminoglycoside Design.

Two crystal structures of ANT(2″), each in complex with AMPCPP, Mn(2+), and either tobramycin or gentamicin are described, which outline ANT (2″)'s specificity for clinically used substrates and complete structural knowledge for the set of enzymes that most frequently confer clinically observed resistance to tobramYcin and Gentamicin.

Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics.

A series of new hybrid structures containing fluoroquinolone (ciprofloxacin) and aminoglycoside (neomycin) antibiotics linked via 1,2,3-triazole moiety were designed and synthesized, and their

2-Deoxystreptamine-containing aminoglycoside antibiotics: recent advances in the characterization and manipulation of their biosynthetic pathways.

This work focuses on recent advances in the characterization of 2-deoxystreptamine-containing aminoglycosides and their biosynthetic enzymes and pathway as well as some chemo-enzymatic and metabolic engineering approaches for the biological production of natural, semi-synthetic, and novel aminglycosides.



The novel enzymatic 3''-N-acetylation of arbekacin by an aminoglycoside 3-N-acetyltransferase of Streptomyces origin and the resulting activity.

The results illuminated a novel aspect of arbekacin distinct from the other aminoglycosides, which showed antibiotic activity as high as that of 2'-N-acetylarbekacin reported previously, whereas 3"-N-acetylamikacin showed no substantial activity.

Enzymatic 2'-N-acetylation of arbekacin and antibiotic activity of its product.

It is believed 2'-N-acetyl ABK has the highest and broadest antibacterial activity, compared with known N- acetylated AGs.

New 2''-amino derivatives of arbekacin, potent aminoglycoside antibiotics against methicillin-resistant Staphylococcus aureus.

Replacement of the 2"-hydroxyl group by amino group in ABKor in dibekacin (DKB, 3',4'-dideoxykanamycin B) was designed to obtain potent derivatives against MRSA.

Synthesis of 3'-deoxykanamycin effective against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa.

The authors attempted, for the first approach, to prepare 3r-0-methylkanamycin (I) by a synthetic method, and suggested that blocking or removal of the hydroxyl group which is phosphorylated will give new compounds effective against the resistant organisms.

BB-K 8, a new semisynthetic aminoglycoside antibiotic.

BB-K8 is a new derivative of kanamycin acylated with L(-)-γ-γ-amino-α-hydroxybutyric acid at the C-1 amino group of the 2-deoxystreptamine moiety that has antibacterial activity generally equal to Kanamycin againstkanamycin-sensitive organisms and is also active against kan amycin- and/or gentamicin-resistant organisms, including Pseudomonas strains.

Biochemical mechanism of resistance to aminoglycosidic antibiotics.

  • H. Umezawa
  • Chemistry, Biology
    Advances in carbohydrate chemistry and biochemistry
  • 1974

Antibacterial activity and nephrotoxicity of two novel 2″-amino derivatives of arbekacin

Results indicate that the 2″-amino group introduced to ABK confers high stabilization to the aminoglycoside-modifying enzymes, while reducing acute and renal toxicities.

A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.

A newly recognized metabolite of arbekacin in arbekACin-resistant strains of MRSA is described, which is shown to be the bifunctional aminoglycoside-modifying enzyme, aminglycoside phosphotransferase (APH(2 ))–aminoglycosid acetyltransferase (AAC(6 )), which simultaneously phosphorylates and acetylates.

Tobramycin adenylyltransferase: a new aminoglycoside-inactivating enzyme from Staphylococcus epidermidis.

Certain strains of Staphylococcus epidermidis resistant to the aminoglycoside antibiotics were shown to contain an enzyme that inactivates the kanamycins, neomycins, butirosins, paromomycin,

3',4'-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa.

synthetic method showed antibacterial activity against E. colt 1629, 1630 carrying R factor and P. aeruginosa for which kanamycin showed no activity. In this communication, the application of a